

# OHMR Research Ethics and Governance Metrics Program



## Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 4 2023  
01/10/2023 – 31/12/2023

NSW Office for Health and Medical Research

## Executive Summary

This report includes strategic and site level performance and compliance metrics that are collected by the Office for Health and Medical Research (OHMR) from NSW Public Health Organisations (PHOs) on studies authorised during the reporting period. The performance of NSW PHOs on health and medical research are reported four times a year, each covering a 3-month period.

## Overall Performance Environment

REGIS is the online platform used to manage ethics and governance applications for all NSW Public Health Organisations. OHMR has undertaken data validation activities with LHD Research Office staff to accurately represent research ethics and governance performance on this platform. These rolling validation activities may result in data reported here to differ from previous reports.

## Update to Metrics Program

As reported previously, OHMR implemented the following changes to the Research Key Performance Indicators (KPIs) for inclusion in the Chief Executives' Services Agreement:

- Number of Greater than Low Risk projects (GLR) processed within application total time
  - 90 days for ethics, 60 days for governance
  - Threshold changes
    - >75% = Performing
    - 55%-75% = Underperforming
    - <55% = Not performing



## Ethics Review Timelines of Human Research in NSW PHOs

### KPI21-03: Ethics Application Approvals - By the Human Research Ethics Committee (HREC) within 90 calendar days

**NSW State Benchmark:** The benchmark for the 2021/22 financial year onwards is for reviewing human research studies by NSW PHO HRECs within 90 calendar days

#### Definition:

The proportion of Ethics applications (excluding LNR) approved by the HREC within 90 calendar days, approved within the reporting period.

#### Context:

The measure will no longer account for clock stops in accordance with the NHMRC Certification Handbook. Instead, the end-to-end time will be measured. Where a valid application is received, the clock starts on the submission closing date for the HREC meeting at which an application will be reviewed. The clock is stopped when the HREC formally notifies the applicant of the final decision.

#### Desired Outcome:

Ensuring timely processing of ethics approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

#### Selection Criteria Summary:

<b>Scope</b>	Human Research Ethics Applications
<b>Frequency</b>	Quarterly
<b>Inclusions</b>	<ul style="list-style-type: none"> <li>Study Type = All</li> <li>Application Type = Greater than low risk</li> <li>Approval Type = Approved/ Approved with conditions within the reporting period</li> </ul>
<b>Exclusions</b>	<ul style="list-style-type: none"> <li>Application Type = Low and negligible risk</li> <li>Approval Type = Not within the reporting period</li> <li>Migrated studies</li> </ul>
<b>Total</b>	Total time is defined as the measurement of the total, unadjusted time from the Submission Closing Date of the first meeting the application is assigned to, to when the final decision notification email is sent.

#### Summary for Metric 3

Ethics review performance of NSW HRECs according to the < **90-day benchmark** for studies approved during the reporting period (**Quarter 4 2023**) are shown in **Table 1**.

During the reporting period, 249 studies (greater than low risk pathway) were approved by a NSW Health HREC with an average review time (total time) of 54 days. Of these 249 studies, 76 (31%) were classified as clinical trials (**Table 2**).

Further breakdown of clinical trial approvals by sponsor type is provided in **Table 3** (by NSW PHOs) and **Table 4** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications is presented in **Table 5**.

**Table 1.** The **90 calendar days benchmark** for approval of human research ethics applications (**greater than low risk**) during the reporting period.

NSW PHOs	Ethics Approval (Q4 2023)					
	All greater than low risk applications					
	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
BLLBRRY	23	21	91%	47	30	17
CINSW	5	4	80%	74	39	34
HNELHD	32	32	100%	23	15	7
ISLHD	0	0	-	-	-	-
JHFMHN	4	4	100%	46	38	8
NBMLHD	3	3	100%	45	30	16
NNSWLHD	1	1	100%	70	32	38
NSLHD	39	39	100%	34	19	15
SCHN	7	7	100%	44	27	17
SESLHD	11	8	73%	66	50	16
SLHD-CCD	14	14	100%	54	24	32
SLHD-RPA	43	43	100%	34	18	15
SVHN	31	22	71%	78	31	47
SWSLHD	16	11	69%	74	59	15
WNSWLHD	4	2	50%	79	52	27
WSLHD	16	12	75%	78	43	35
<b>TOTAL</b>	<b>249</b>	<b>223</b>	<b>90%</b>	<b>54</b>	<b>33</b>	<b>20</b>

**Table 2. The 90 calendar days benchmark for the approval of clinical trials (greater than low risk) during the reporting period.**

NSW PHOs	Ethics Approval (Q4 2023)					
	Clinical Trials					
	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
BLLBRRY	23	21	91%	47	30	17
CINSW	0	0	-	-	-	-
HNELHD	7	7	100%	27	18	10
ISLHD	0	0	-	-	-	-
JHFMHN	0	0	-	-	-	-
NBMLHD	0	0	-	-	-	-
NNSWLHD	0	0	-	-	-	-
NSLHD	5	5	100%	30	22	8
SCHN	2	2	100%	32	20	13
SESLHD	1	0	0%	92	47	45
SLHD-CCD	3	3	100%	71	29	42
SLHD-RPA	16	16	100%	41	21	20
SVHN	9	8	89%	56	24	33
SWSLHD	4	2	50%	89	72	17
WNSWLHD	1	0	0%	104	73	31
WSLHD	5	5	100%	66	42	24
<b>TOTAL</b>	<b>76</b>	<b>69</b>	<b>91%</b>	<b>49</b>	<b>29</b>	<b>20</b>

**Table 3.** Breakdown of NSW PHO performances in **clinical trial approvals** (greater than low risk) during the reporting period **by sponsor type**

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average	Average	Total # of Applications	Average	Average	Total # of Applications	Average	Average
		Research Office Time (days)	Total Time (days)		Research Office Time (days)	Total Time (days)		Research Office Time (days)	Total Time (days)
BLLBRRY	0	-	-	23	30	47	0	-	-
CINSW	0	-	-	0	-	-	0	-	-
HNELHD	1	18	25	3	20	36	3	15	20
ISLHD	0	-	-	0	-	-	0	-	-
JHFMHN	0	-	-	0	-	-	0	-	-
NBMLHD	0	-	-	0	-	-	0	-	-
NNSWLHD	0	-	-	0	-	-	0	-	-
NSLHD	2	35	54	0	-	-	3	14	14
SCHN	0	-	-	1	23	35	1	16	29
SESLHD	0	-	-	1	47	92	0	-	-
SLHD-CCD	0	-	-	1	37	62	2	25	76
SLHD-RPA	9	22	39	2	17	39	5	23	47
SVHN	2	19	25	5	27	75	2	23	41
SWSLHD	0	-	-	4	72	89	0	-	-
WNSWLHD	0	-	-	0	-	-	1	73	104
WSLHD	1	41	85	4	43	62	0	-	-
<b>Grand Total</b>	<b>15</b>	<b>24</b>	<b>41</b>	<b>44</b>	<b>34</b>	<b>55</b>	<b>17</b>	<b>22</b>	<b>41</b>

**Table 4.** Quarterly **clinical trial approvals** (greater than low risk) in the last 3 reporting period (between 01/04/2023 and 31/12/2023), **by sponsor type**

	Q2 2023			Q3 2023			Q4 2023		
Sponsor Type	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
Collaborative Group	10	37	72	18	31	51	15	24	41
Commercial Entity	46	33	56	48	30	49	44	34	55
Investigator Initiated	32	32	57	27	27	48	17	22	41
Total	88	33	58	93	29	49	76	26	43

**Table 5. Historical performance** of NSW PHOs against **the old and new benchmarks** for the review and approval of human research ethics applications (greater than low risk) in the last 3 reporting period (between 01/04/2023 and 31/12/2023).

NSW PHOs		Q2 2023							Q3 2023							Q4 2023						
		Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)		
			Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)
BLLBRRY	21	20	95%	22	20	95%	48	27	25	93%	18	24	89%	47	23	21	91%	17	21	91%	47	
CINSW	8	6	75%	28	6	75%	77	5	5	100%	15	5	100%	49	5	4	80%	34	4	80%	74	
HNELHD	29	29	100%	14	29	100%	31	22	21	95%	14	22	100%	30	32	32	100%	7	32	100%	23	
ISLHD	3	3	100%	27	3	100%	67	5	5	100%	18	5	100%	54	0	0	-	-	0	-	-	
JHFMHN	4	4	100%	3	4	100%	46	1	0	0%	50	1	100%	88	4	4	100%	8	4	100%	46	
NBMLHD	3	2	67%	35	3	100%	76	3	3	100%	23	1	33%	93	3	3	100%	16	3	100%	45	
NNSWLHD	2	2	100%	32	1	50%	86	2	2	100%	7	2	100%	48	1	1	100%	38	1	100%	70	
NSLHD	31	27	87%	20	27	87%	52	31	31	100%	14	31	100%	40	39	38	97%	15	39	100%	34	
SCHN	12	11	92%	27	12	100%	59	22	21	95%	18	22	100%	46	7	7	100%	17	7	100%	44	
SESLHD	13	13	100%	15	13	100%	64	10	9	90%	20	7	70%	73	11	10	91%	16	8	73%	66	
SLHD-CCD	7	5	71%	32	7	100%	57	6	5	83%	29	6	100%	52	14	10	71%	32	14	100%	54	
SLHD-RPA	53	53	100%	18	53	100%	37	44	42	95%	17	44	100%	33	43	42	98%	15	43	100%	34	
SVHN	13	8	62%	37	11	85%	65	16	12	75%	29	13	81%	55	31	20	65%	47	22	71%	78	
SWSLHD	14	13	93%	19	12	86%	57	12	12	100%	13	10	83%	53	16	16	100%	15	11	69%	74	
WNSWLHD	5	5	100%	12	5	100%	39	4	4	100%	22	4	100%	69	4	3	75%	27	2	50%	79	
WSLHD	27	21	78%	26	20	74%	75	24	22	92%	26	21	88%	70	16	12	75%	35	12	75%	78	
TOTAL	245	222	91%	21	226	92%	52	234	219	94%	19	218	93%	48	249	223	90%	21	223	88%	54	





## Site-specific Assessment (SSA) Authorisation Timelines of Human Research Projects in NSW PHOs

### KPI21-04: Research Governance Application Authorisations – SSA Authorisations within 60 calendar days

**NSW State Benchmark:** The benchmark for the 2021/22 financial year onwards for authorisation of SSA applications is 60 calendar days

#### Definition:

The proportion of site-specific assessment (SSA) applications (excluding lower to negligible risk) authorised by the Research Governance Office (RGO) within 60 calendar days, authorised within the reporting period.

#### Context:

The measure will no longer account for clock stops in accordance with the National Health and Medical Research Council Certification. Handbook. Instead, the end-to-end time will be measured. The SSA application received date is the date the RGO or designee receives an SSA application from a researcher regardless of whether it is complete and/or deemed valid. The clock is stopped when the final SSA decision letter is provided to the site principal investigator.

#### Desired Outcome:

Ensuring timely processing of site approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

#### Selection Criteria Summary:

##### Scope

Site-specific assessment (SSA) applications

##### Frequency

Quarterly

##### Inclusions

- Study Type = All
- Application Type = Greater than low risk
- Approval Type = “Authorised” or “authorised with conditions” within the reporting period

##### Exclusions

- Application Type = Low and negligible risk
- Migrated studies

#### Total Time:

Total time is the measurement of the total, unadjusted time from the Submission Date to when the final decision notification email is sent granting approval.

#### Summary:

SSA review performance of NSW PHOs according to the **<60-day benchmark** for studies authorised during the reporting period (**Quarter 4 2023**) are shown in **Table 6**. During the reporting period,

**592** studies (greater than low risk pathway) were authorised in NSW PHOs with an average review time (total time) of **40** days.

Of these **592** studies, **268** were classified as clinical trials (**Table 7**).

Further breakdown of clinical trial SSA authorisations by sponsor type is provided in **Table 8** (by NSW PHOs) and **Table 9** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of governance applications is presented in **Table 10**.

**Table 6: The 60 calendar days benchmark for authorisation of governance applications (greater than low risk) during the reporting period.**

NSW PHOs	SSA Approvals (Q4 2023)							
	All greater than low risk applications							
		60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
	Total Number of Applications	Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
Calvary	12	12	100%	11	9	1	2	-1
CCLHD	11	10	91%	28	9	6	0	13
FWLHD	0	0	-	-	-	-	-	-
HNELHD	50	49	98%	30	14	5	1	11
ISLHD	19	18	95%	8	1	1	0	6
JHFMHN	0	0	-	-	-	-	-	-
MLHD	10	10	100%	32	6	10	2	14
MNCLHD	8	8	100%	27	7	2	3	15
NBMLHD	20	17	85%	58	32	6	1	18
NNSWLHD	4	4	100%	39	5	1	7	27
NSLHD	60	53	88%	38	14	9	4	12
NSWHPTH	2	1	50%	74	28	28	2	16
SCHN	58	52	90%	35	9	10	0	16
SESLHD	52	41	79%	48	14	11	1	21
SLHD-CCD	29	29	100%	25	8	7	5	4
SLHD-RPA	93	90	97%	26	8	13	2	2
SNSWLHD	2	1	50%	46	38	8	0	0
SVHN	34	23	68%	54	10	11	1	31
SWSLHD	43	14	33%	92	54	14	1	21
WNSWLHD	8	7	88%	22	13	17	0	12
WSLHD	77	63	82%	40	9	13	3	15
<b>TOTAL</b>	<b>592</b>	<b>508</b>	<b>86%</b>	<b>40</b>	<b>14</b>	<b>10</b>	<b>2</b>	<b>13</b>

**Table 7: The 60 calendar days benchmark for the authorisation of clinical trials (greater than low risk) during the reporting period.**

NSW PHOs	SSA Approvals (Q4 2023) Clinical Trials							
	Total Number of Applications	60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
		Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
CALVARY	12	12	100%	11	9	1	2	-1
CCLHD	7	7	100%	13	5	6	0	2
FWLHD	0	0	-	-	-	-	-	-
HNELHD	15	15	100%	38	17	4	1	17
ISLHD	10	10	100%	5	1	1	0	3
JHFMHN	0	0	-	-	-	-	-	-
MLHD	2	2	100%	38	11	15	1	12
MNCLHD	5	5	100%	17	11	3	5	-1
NBMLHD	10	10	100%	48	38	10	2	-2
NNSWLHD	3	3	100%	52	6	1	9	36
NSLHD	17	16	94%	38	14	9	4	12
NSWHPH	1	1	1	53	28	6	4	15
SCHN	18	16	89%	45	10	11	1	21
SESLHD	29	23	79%	48	15	16	1	15
SLHD-CCD	10	10	100%	26	15	10	12	-12
SLHD-RPA	38	36	95%	35	13	19	4	0
SNSWLHD	1	0	0%	70	62	8	0	0
SVHN	15	11	73%	40	11	13	1	16
SWSLHD	25	7	28%	97	63	17	0	12
WNSWLHD	4	4	100%	14	18	33	0	4
WSLHD	46	39	85%	42	11	13	3	15
<b>TOTAL</b>	<b>268</b>	<b>229</b>	<b>85%</b>	<b>43</b>	<b>18</b>	<b>12</b>	<b>2</b>	<b>10</b>

**Table 8.** NSW PHO performances in clinical trial authorisations (greater than low risk) during the reporting period, by sponsor type.

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
ASNSW	0	-	-	0	-	-	0	-	-
CALVARY	4	13	14	8	7	9	0	-	-
CCLHD	3	7	11	2	2	14	2	6	16
FWLHD	0	-	-	0	-	-	0	-	-
HNELHD	4	18	39	4	17	26	7	16	45
ISLHD	1	0	2	4	0	6	5	2	4
JHFMHN	0	-	-	0	-	-	0	-	-
MLHD	1	9	55	0	-	-	1	12	20
MNCLHD	1	10	10	3	5	16	1	28	29
NBMLHD	2	41	45	8	37	49	0	-	-
NNSWLHD	0	-	-	1	19	53	2	0	52
NSLHD	5	13	40	8	16	26	4	10	62
NSWHPH	0	-	-	0	-	-	0	-	-
SCHN	2	5	40	10	10	37	6	12	59
SESLHD	15	14	55	12	17	44	2	16	30
SLHD-CCD	4	21	31	4	10	22	2	15	25
SLHD-RPA	5	12	25	19	14	28	14	13	48
SNSWLHD	0	-	-	0	-	-	1	62	70
SVHN	2	15	42	10	10	32	3	11	69
SWSLHD	11	78	120	13	48	75	1	88	129
WNSWLHD	2	27	12	1	2	9	1	15	22
WSLHD	6	12	52	33	10	29	7	12	95
<b>Total</b>	<b>69</b>	<b>24</b>	<b>51</b>	<b>140</b>	<b>17</b>	<b>35</b>	<b>59</b>	<b>15</b>	<b>53</b>

**Table 9.** Quarterly clinical trial authorisations (greater than low risk applications) approved during the last 3 reporting period, by sponsor type

	Q2 2023			Q3 2023			Q4 2023		
Sponsor Type	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time
Collaborative Group	41	12	56	50	12	43	69	24	51
Commercial Entity	118	8	28	118	9	28	140	17	35
Investigator Initiated	62	13	60	60	19	44	59	15	53
Total	221	10	42	228	12	35	268	18	47

**Table 10.** Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of SSA applications (greater than low risk) for the last 3 reporting periods ( between 01/04/2023 and 31/12/2023).

	Q2 2023							Q3 2023							Q4 2023						
LHD	Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (without clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)		
		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)
ASNSW	0	0	-	-	0	-	-	3	1	0.3333	64	1	33%	158	0	0	-	-	0	-	-
CALVARY	14	13	93%	6	13	93%	18	7	6	86%	8	7	100%	11	12	9	75%	9	12	100%	11
CCLHD	14	13	93%	5	14	100%	12	11	10	91%	5	11	100%	13	11	9	82%	9	10	91%	28
FWLHD	0	0	-	-	0	-	-	1	1	100%	11	1	100%	11	0	0	-	-	0	-	-
HNELHD	35	25	71%	10	34	97%	25	33	21	64%	13	33	100%	27	50	27	54%	14	49	98%	30
ISLHD	18	18	100%	1	18	100%	7	17	17	100%	2	17	100%	5	19	19	100%	1	18	95%	8
JHFMHN	2	0	0%	29	2	100%	29	2	0	0	46	2	100%	51	0	0	-	-	0	-	-
MLHD	1	1	100%	7	0	0%	80	4	3	75%	11	4	100%	18	10	9	90%	6	10	100%	32
MNCLHD	12	10	83%	10	10	83%	42	6	6	100%	6	6	100%	19	8	7	88%	7	7	88%	27
NBMLHD	7	3	43%	20	7	100%	46	7	1	14%	36	7	100%	53	20	7	35%	32	17	85%	58
NNSWLHD	4	3	75%	5	3	75%	33	9	6	67%	13	9	100%	22	4	3	75%	5	4	100%	39
NSLHD	29	20	69%	11	25	86%	40	47	27	57%	14	44	94%	30	60	36	60%	14	53	88%	38
NSWHPH	7	3	43%	19	1	14%	124	12	1	8%	35	10	83%	61	2	0	0%	28	1	50%	74
SCHN	25	22	88%	10	25	100%	38	21	17	81%	9	21	100%	34	58	47	81%	9	52	90%	35
SESLHD	41	33	80%	8	35	85%	42	38	22	58%	13	26	68%	49	52	34	65%	14	41	79%	48
SLHD-CCD	20	19	95%	3	20	100%	29	16	14	88%	5	16	100%	25	29	23	79%	8	29	100%	25
SLHD-RPA	50	49	98%	2	50	100%	22	60	51	85%	6	60	100%	24	93	75	81%	8	90	97%	26
SNSWLHD	1	0	0%	77	0	0%	119	0	0	-	-	0	-	-	2	1	50%	38	1	50%	46
SVHN	39	34	87%	10	28	72%	66	41	32	78%	19	28	68%	60	34	25	74%	10	23	68%	54
SWSLHD	43	1	2%	30	39	91%	62	47	8	17%	28	39	83%	50	43	6	14%	54	14	33%	92
WNSWLHD	5	5	100%	2	4	80%	22	8	8	100%	5	8	100%	11	8	5	63%	13	7	88%	22
WSLHD	66	55	83%	9	56	85%	48	71	63	89%	9	63	89%	34	77	65	84%	9	63	82%	40
<b>Total</b>	<b>433</b>	<b>327</b>	<b>76%</b>	<b>10</b>	<b>384</b>	<b>89%</b>	<b>40</b>	<b>461</b>	<b>315</b>	<b>68%</b>	<b>14</b>	<b>413</b>	<b>90%</b>	<b>36</b>	<b>592</b>	<b>407</b>	<b>69%</b>	<b>14</b>	<b>508</b>	<b>86%</b>	<b>40</b>

A list of NSW PHOs names and abbreviations that review and/or authorise human research studies:

Human Research Ethics Committee/ Research Governance Office Names	Abbreviation used in the tables	Ethics	Site
Ambulance Service of NSW	ASNSW		Yes
Bellberry	BLLBRRY	Yes	
Calvary Mater Hospital Newcastle	CALVARY		Yes
Central Coast LHD	CCLHD		Yes
NSW Population & Health Services Research Ethics Committee	CINSW	Yes	
Greater Western LHD	WNSWLHD	Yes	Yes
Hammond Care	HCARE		Yes
Hunter New England LHD	HNELHD	Yes	Yes
Justice Health & Forensic Mental Health Network	JHFMHN	Yes	Yes
Mid North Coast LHD	MNCLHD		Yes
Murrumbidgee LHD	MLHD		Yes
Northern NSW LHD	NNSWLHD	Yes	Yes
Nepean Blue Mountains LHD	NBMLHD	Yes	Yes
Northern Sydney LHD	NSLHD	Yes	Yes
NSW Health Pathology	NSWHPTH		Yes
Royal Rehabilitation Centre Sydney HREC	RRCS	Yes	
Sydney Children's Hospitals Network	SCHN	Yes	Yes
South Eastern Sydney LHD	SESLHD	Yes	Yes
Sydney LHD (Concord Zone)	SLHD – CCD	Yes	Yes
Sydney LHD (RPAH Zone)	SLHD – RPA	Yes	Yes
Southern NSW LHD	SNSWLHD		Yes
St Vincent's Hospital	SVHN	Yes	Yes
South Western Sydney LHD	SWSLHD	Yes	Yes
Illawarra Shoalhaven LHD (joint committee with University of Wollongong)	ISLHD	Yes	Yes
Western Sydney LHD	WSLHD	Yes	Yes



For more information

This report has been prepared by the Research Ethics and Governance Unit in Office for Health and Medical Research.

For further enquiries and for the use of this report please contact:

**James Cokayne**

**Principal Policy Officer**

**Research Ethics and Governance Unit**

**Office for Health and Medical Research**

[Tel \(02\) 9391 9920](tel:0293919920) | [james.cokayne@health.nsw.gov.au](mailto:james.cokayne@health.nsw.gov.au)

**Yagiz Aksoy**

**Senior Policy Officer**

**Research Ethics and Governance Unit**

**Office for Health and Medical Research**

[Tel \(02\) 9461 7887](tel:0294617887) | [yagiz.aksoy@health.nsw.gov.au](mailto:yagiz.aksoy@health.nsw.gov.au)

**Deb Aldridge**

**Policy Officer and Data Analyst**

**Research Ethics and Governance Unit**

**Office for Health and Medical Research**

[Tel \(02\) 93919854](tel:0293919854) | [deborah.aldridge@health.nsw.gov.au](mailto:deborah.aldridge@health.nsw.gov.au)